Skip to main content
Top
Published in: Drugs & Aging 1/2017

01-01-2017 | Therapy in Practice

How Antibiotics Should be Prescribed to Hospitalized Elderly Patients with Community-Acquired Pneumonia

Author: Forest W. Arnold

Published in: Drugs & Aging | Issue 1/2017

Login to get access

Abstract

Elderly patients hospitalized with community-acquired pneumonia (CAP) should be administered antimicrobials in the emergency department prior to transfer to the ward or intensive care unit (ICU). For ward patients, a β-lactam with a macrolide or a respiratory fluoroquinolone alone should be given to cover typical and atypical pathogens. For ICU patients, a β-lactam with either a macrolide or a fluoroquinolone should be given. Other regimens are indicated if methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa is a concern. Patients who are hemodynamically stable and can tolerate oral intake can be considered for switch therapy as well as discharge if other co-morbidities are stable and a safe disposition plan exists. A number of special concerns for the elderly include noting adverse effects from antimicrobials, being watchful of comorbidity exacerbations, and vaccinating for pneumococcus and influenza.
Literature
1.
go back to reference Eurich DT, Marrie TJ, Minhas-Sandhu JK, et al. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med. 2015;192(5):597–604.CrossRefPubMed Eurich DT, Marrie TJ, Minhas-Sandhu JK, et al. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med. 2015;192(5):597–604.CrossRefPubMed
2.
go back to reference Osler W. The principles and practice of medicine. 3rd ed. New York: D Appelton and Co; 1899. Osler W. The principles and practice of medicine. 3rd ed. New York: D Appelton and Co; 1899.
3.
go back to reference Dunn HL. National and mortality data for the United States. Vital statistics of the United States; part 1. Washington D.C.: National Office of Vital Statistics; 1946. Dunn HL. National and mortality data for the United States. Vital statistics of the United States; part 1. Washington D.C.: National Office of Vital Statistics; 1946.
4.
go back to reference Heron M. Deaths: Leading causes for 2014. National vital statistics reports, vol 65, no 5. Hyattsville: National Center for Health Statistics; 2016. Heron M. Deaths: Leading causes for 2014. National vital statistics reports, vol 65, no 5. Hyattsville: National Center for Health Statistics; 2016.
6.
go back to reference Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.CrossRefPubMed Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.CrossRefPubMed
7.
go back to reference Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278(23):2080–4.CrossRefPubMed Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278(23):2080–4.CrossRefPubMed
8.
go back to reference Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164(6):637–44.CrossRefPubMed Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164(6):637–44.CrossRefPubMed
9.
go back to reference Lee JS, Nsa W, Hausmann LR, et al. Quality of care for elderly patients hospitalized for pneumonia in the United States, 2006 to 2010. JAMA Intern Med. 2014;174(11):1806–14.CrossRefPubMed Lee JS, Nsa W, Hausmann LR, et al. Quality of care for elderly patients hospitalized for pneumonia in the United States, 2006 to 2010. JAMA Intern Med. 2014;174(11):1806–14.CrossRefPubMed
10.
go back to reference Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086–93.CrossRefPubMed Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086–93.CrossRefPubMed
11.
go back to reference Lim WS, Baudouin SV, George RC, et al. Guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):S1–55.CrossRef Lim WS, Baudouin SV, George RC, et al. Guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):S1–55.CrossRef
12.
go back to reference Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123(5):1503–11.CrossRefPubMed Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123(5):1503–11.CrossRefPubMed
13.
go back to reference Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33(1):153–9.CrossRefPubMed Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33(1):153–9.CrossRefPubMed
14.
go back to reference Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004;170(4):440–4.CrossRefPubMed Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004;170(4):440–4.CrossRefPubMed
15.
go back to reference Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J. 2004;11(8):589–93.CrossRefPubMed Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J. 2004;11(8):589–93.CrossRefPubMed
16.
go back to reference Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159(21):2562–72.CrossRefPubMed Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999;159(21):2562–72.CrossRefPubMed
17.
go back to reference Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther. 2000;22:872–8.CrossRefPubMed Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther. 2000;22:872–8.CrossRefPubMed
18.
go back to reference Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012;55(3):371–80.CrossRefPubMed Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012;55(3):371–80.CrossRefPubMed
19.
go back to reference Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class not obviously important in outpatient pneumonia: a meta-analysis. Eur Respir J. 2008;31(5):1068–76.CrossRefPubMed Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class not obviously important in outpatient pneumonia: a meta-analysis. Eur Respir J. 2008;31(5):1068–76.CrossRefPubMed
20.
go back to reference Caffrey AR, Morrill HJ, Puzniak LA, et al. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy. 2014;34(5):473–80.CrossRefPubMed Caffrey AR, Morrill HJ, Puzniak LA, et al. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy. 2014;34(5):473–80.CrossRefPubMed
21.
go back to reference Peyrani P, Wiemken TL, Kelley R, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care. 2014;18(3):R118.CrossRefPubMedPubMedCentral Peyrani P, Wiemken TL, Kelley R, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care. 2014;18(3):R118.CrossRefPubMedPubMedCentral
22.
go back to reference Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155(12):1273–6.CrossRefPubMed Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155(12):1273–6.CrossRefPubMed
23.
go back to reference Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002;162(11):1278–84.CrossRefPubMed Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med. 2002;162(11):1278–84.CrossRefPubMed
24.
go back to reference Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159(20):2449–54.CrossRefPubMed Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159(20):2449–54.CrossRefPubMed
25.
go back to reference Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med. 2009;169(16):1515–24.CrossRefPubMed Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med. 2009;169(16):1515–24.CrossRefPubMed
26.
go back to reference Egger ME, Myers JA, Arnold FW, et al. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for community-aquired pneumonia. BMC Med Inform Decis Mak. 2016;16:34.CrossRefPubMedPubMedCentral Egger ME, Myers JA, Arnold FW, et al. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for community-aquired pneumonia. BMC Med Inform Decis Mak. 2016;16:34.CrossRefPubMedPubMedCentral
27.
go back to reference Rossio R, Franchi C, Ardoino I, et al. Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. Eur J Intern Med. 2015;26(5):330–7.CrossRefPubMed Rossio R, Franchi C, Ardoino I, et al. Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. Eur J Intern Med. 2015;26(5):330–7.CrossRefPubMed
28.
go back to reference Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773–81.CrossRefPubMed Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773–81.CrossRefPubMed
29.
go back to reference Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182–7.CrossRefPubMed Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182–7.CrossRefPubMed
30.
go back to reference Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8(6):e1001048.CrossRefPubMedPubMedCentral Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8(6):e1001048.CrossRefPubMedPubMedCentral
31.
32.
go back to reference Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case–control study through a general practice database. Eur Heart J. 2008;29(1):96–103.CrossRefPubMed Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case–control study through a general practice database. Eur Heart J. 2008;29(1):96–103.CrossRefPubMed
33.
go back to reference Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response a randomized clinical trial. JAMA. 2015;313(7):677–86.CrossRefPubMed Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response a randomized clinical trial. JAMA. 2015;313(7):677–86.CrossRefPubMed
34.
go back to reference Marti C, Grosgurin O, Harbarth S, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2015;10(12):e0144032.CrossRefPubMedPubMedCentral Marti C, Grosgurin O, Harbarth S, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2015;10(12):e0144032.CrossRefPubMedPubMedCentral
35.
go back to reference Valley TS, Walkey AJ, Lindenauer PK, et al. Association between noninvasive ventilation and mortality among older patients with pneumonia. Crit Care Med. 2016. doi:10.1097/CCM.0000000000002076. (Epub ahead of print). Valley TS, Walkey AJ, Lindenauer PK, et al. Association between noninvasive ventilation and mortality among older patients with pneumonia. Crit Care Med. 2016. doi:10.​1097/​CCM.​0000000000002076​. (Epub ahead of print).
36.
go back to reference Kim DK, Bridges CB, Harriman KH, et al. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med. 2016;164(3):184–94.CrossRefPubMed Kim DK, Bridges CB, Harriman KH, et al. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med. 2016;164(3):184–94.CrossRefPubMed
Metadata
Title
How Antibiotics Should be Prescribed to Hospitalized Elderly Patients with Community-Acquired Pneumonia
Author
Forest W. Arnold
Publication date
01-01-2017
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 1/2017
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-016-0423-9

Other articles of this Issue 1/2017

Drugs & Aging 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.